These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 28641776)

  • 1. The 'Field Hypothesis': rebound activity after stopping disease-modifying therapies.
    Giovannoni G; Hawkes C; Waubant E; Lublin F
    Mult Scler Relat Disord; 2017 Jul; 15():A1-A2. PubMed ID: 28641776
    [No Abstract]   [Full Text] [Related]  

  • 2. Dengue fever in patients with multiple sclerosis taking fingolimod or natalizumab.
    Fragoso YD; Gama PDD; Gomes S; Khouri JMN; Matta APDC; Fernanda Mendes M; Stella CRAV
    Mult Scler Relat Disord; 2016 Mar; 6():64-65. PubMed ID: 27063625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe rebound after withdrawal of fingolimod treatment in patients with multiple sclerosis.
    Gündüz T; Kürtüncü M; Eraksoy M
    Mult Scler Relat Disord; 2017 Jan; 11():1-3. PubMed ID: 28104247
    [No Abstract]   [Full Text] [Related]  

  • 4. PML: The Dark Side of Immunotherapy in Multiple Sclerosis.
    Warnke C; Olsson T; Hartung HP
    Trends Pharmacol Sci; 2015 Dec; 36(12):799-801. PubMed ID: 26497099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.
    Hatcher SE; Waubant E; Nourbakhsh B; Crabtree-Hartman E; Graves JS
    JAMA Neurol; 2016 Jul; 73(7):790-4. PubMed ID: 27135594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis.
    Frisell T; Forsberg L; Nordin N; Kiesel C; Alfredsson L; Askling J; Hillert J; Olsson T; Piehl F
    Mult Scler; 2016 Jan; 22(1):85-93. PubMed ID: 25921036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease modifying therapies for relapsing multiple sclerosis.
    Wingerchuk DM; Weinshenker BG
    BMJ; 2016 Aug; 354():i3518. PubMed ID: 27549763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe disease exacerbations in patients with multiple sclerosis after discontinuing fingolimod.
    Członkowska A; Smoliński Ł; Litwin T
    Neurol Neurochir Pol; 2017; 51(2):156-162. PubMed ID: 28209440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis.
    Chitnis T; Arnold DL; Banwell B; Brück W; Ghezzi A; Giovannoni G; Greenberg B; Krupp L; Rostásy K; Tardieu M; Waubant E; Wolinsky JS; Bar-Or A; Stites T; Chen Y; Putzki N; Merschhemke M; Gärtner J;
    N Engl J Med; 2018 Sep; 379(11):1017-1027. PubMed ID: 30207920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumefactive demyelinating lesions: A comprehensive review.
    Algahtani H; Shirah B; Alassiri A
    Mult Scler Relat Disord; 2017 May; 14():72-79. PubMed ID: 28619436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fingolimod treatment after natalizumab-related progressive multifocal leukoencephalopathy: three new cases.
    Peaureaux D; Pignolet B; Biotti D; Bucciarelli F; Gaina J; Bucur C; Clanet M; Martin-Blondel G; Brassat D
    Mult Scler; 2015 Apr; 21(5):671-2. PubMed ID: 25305251
    [No Abstract]   [Full Text] [Related]  

  • 12. Disease reactivation following fingolimod withdrawal in multiple sclerosis: Two case reports.
    Forci B; Mariottini A; Mechi C; Massacesi L; Repice A
    Mult Scler Relat Disord; 2017 Jul; 15():24-26. PubMed ID: 28641768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Agents for Relapsing Forms of Multiple Sclerosis.
    Straus Farber R; Harel A; Lublin F
    Annu Rev Med; 2016; 67():309-21. PubMed ID: 26394285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneous cryptococcosis in a patient taking fingolimod for multiple sclerosis: Here come the opportunistic infections?
    Carpenter AF; Goodwin SJ; Bornstein PF; Larson AJ; Markus CK
    Mult Scler; 2017 Feb; 23(2):297-299. PubMed ID: 28165320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Fingolimod].
    Hashi Y; Kondo T
    Nihon Rinsho; 2015 Sep; 73 Suppl 7():205-11. PubMed ID: 26480701
    [No Abstract]   [Full Text] [Related]  

  • 16. [Disease modifying drugs in multiple sclerosis and pregnancy].
    Tur C; Tintoré M; Aguilera C
    Med Clin (Barc); 2012 Sep; 139(7):316-8. PubMed ID: 22743277
    [No Abstract]   [Full Text] [Related]  

  • 17. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
    Baroncini D; Ghezzi A; Annovazzi PO; Colombo B; Martinelli V; Minonzio G; Moiola L; Rodegher M; Zaffaroni M; Comi G
    Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on therapeutic options for multiple sclerosis.
    McCoyd M
    Neurol Clin; 2013 Aug; 31(3):827-45. PubMed ID: 23896508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study.
    Paolicelli D; Manni A; Direnzo V; D'Onghia M; Tortorella C; Zoccolella S; Trojano M
    J Clin Pharmacol; 2015 Oct; 55(10):1131-6. PubMed ID: 25903516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis.
    Bargiela D; Bianchi MT; Westover MB; Chibnik LB; Healy BC; De Jager PL; Xia Z
    Neurology; 2017 Feb; 88(7):677-684. PubMed ID: 28087821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.